PFE - IPO Update: Checkmate Pharmaceuticals Readies $75 Million IPO
Quick Take
Checkmate Pharmaceuticals (CMPI) intends to raise $75 million from the sale of its common stock stock in an IPO, according to an amended registration statement.
The company is advancing a biologic particle treatment for melanomas and head & neck squamous cell carcinomas.
CMPI’s pipeline is quite promising and the IPO is not overpriced, so for life science investors with a patient hold time frame, the IPO may be worth considering.
Company & Technology
Cambridge, Massachusetts-based Checkmate was founded to develop its CMP-001 candidate, a Toll-like receptor 9, TLR9 'agonist delivered